You just read:

Shire Receives European Approval for Label Extension of CINRYZE®▼(C1 inhibitor [human]) to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Paediatric Patients with HAE

News provided by

Shire plc

Mar 16, 2017, 02:00 ET